http://orcid.org/0000-0003-3521-102X
Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yunjian Li, Liang Du, Kaiqin Ye, Xiao Sun, Lei Hu, Shan Gao & Haiming Dai. (2023) AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis. Hematology 28:1.
Read now
Read now
Yaqi Xu, Xiaoli Feng, Qian Zhou, Wen Jiang, Yibo Dai, Yang Jiang, Xiaoli Liu, Shuo Li, Yongjing Wang, Fang Wang, Ai Li & Chengyun Zheng. (2020) Novel Small Molecular Compound AE-848 Potently Induces Human Multiple Myeloma Cell Apoptosis by Modulating the NF-κB and PI3K/Akt/mTOR Signaling Pathways. OncoTargets and Therapy 13, pages 13063-13075.
Read now
Read now
Articles from other publishers (40)
Ziyu Ji, Jianlin Shen, Yujian Lan, Qian Yi & Huan Liu. (2023) Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm 4:4.
Crossref
Crossref
Daniel García-Sánchez, Alberto González-González, Ana Alfonso-Fernández, Mónica Del Dujo-Gutiérrez & Flor M Pérez-Campo. (2023) Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression. World Journal of Stem Cells 15:5, pages 421-437.
Crossref
Crossref
Francisco Aguayo, Francisco Perez-Dominguez, Julio C. Osorio, Carolina Oliva & Gloria M. Calaf. (2023) PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications. Biology 12:5, pages 672.
Crossref
Crossref
Xiaoli Qian, Yang Yang, Yingfen Deng, Yali Liu, Yuwen Zhou, Fang Han, Yue Xu & Hongjian Yuan. (2023) SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial‑mesenchymal transition and PI3K/AKT pathway activation. Experimental and Therapeutic Medicine 25:6.
Crossref
Crossref
Aneta Szudy-Szczyrek, Radosław Mlak, Marcin Mazurek, Tomasz Krajka, Sylwia Chocholska, Paulina Bitkowska, Marta Jutrzenka, Michał Szczyrek, Iwona Homa-Mlak, Andrzej Krajka, Teresa Małecka-Massalska & Marek Hus. (2023) The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma. Cells 12:7, pages 1029.
Crossref
Crossref
Giada Bianchi,Matthew Ho,Kenneth C. Anderson. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
313
330
.
Yu-tong Wang, Bin Chu, Tian-guan Zhou, Min-qiu Lu, Lei Shi, Shan Gao, Li-juan Fang, Qiu-qing Xiang, Xin- Zhao, Meng-zhen Wang, Kai Sun & Li Bao. (2023) Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study. Frontiers in Oncology 13.
Crossref
Crossref
Young Yun Jung, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Jae‐Young Um, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Kanchugarakoppal S. Rangappa & Kwang Seok Ahn. (2022) Brucein D imparts a growth inhibitory effect in multiple myeloma cells by abrogating the Akt‐driven signaling pathway. IUBMB Life 75:2, pages 149-160.
Crossref
Crossref
Hayder M. Al‐Kuraishy, Ali I. Al‐Gareeb, Ali A Mohammed, Athanasios Alexiou, Marios Papadakis & Gaber El‐Saber Batiha. (2022) The potential link between Covid‐19 and multiple myeloma: A new saga. Immunity, Inflammation and Disease 10:12.
Crossref
Crossref
Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, Kristine Misund, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Eivind Coward, Anders Waage, Kjetil Taskén & Sigrid S. Skånland. (2022) Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Frontiers in Oncology 12.
Crossref
Crossref
Bruno Toson, Isadora S. Fortes, Rafael Roesler & Saulo F. Andrade. (2022) Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials. Pharmacological Research 183, pages 106403.
Crossref
Crossref
Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh & Alessandro Laganà. (2022) Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Luca Heinemann, Klara Maria Möllers, Helal Mohammed Mohammed Ahmed, Lanying Wei, Kaiyan Sun, Subbaiah Chary Nimmagadda, Daria Frank, Anja Baumann, Alexandra M. Poos, Martin Dugas, Julian Varghese, Marc-Steffen Raab & Cyrus Khandanpour. (2022) Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. Frontiers in Oncology 12.
Crossref
Crossref
Dominique B. Hoelzinger, Sophia J. Quinton, Denise K. Walters, Trupti Vardam-Kaur, Renee C. Tschumper, Henrique Borges da Silva & Diane F. Jelinek. (2022) Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology. Blood Advances 6:11, pages 3458-3471.
Crossref
Crossref
Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai & Junya Kuroda. (2022) The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences 23:6, pages 2919.
Crossref
Crossref
Lingjun Meng, Guiying Gu & Lintao Bi. (2022) Transient receptor potential channels in multiple myeloma (Review). Oncology Letters 23:4.
Crossref
Crossref
Darren Pan & Joshua Richter. (2022) Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Frontiers in Oncology 11.
Crossref
Crossref
智慧 李. (2022) Simultaneous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review. Advances in Clinical Medicine 12:01, pages 376-380.
Crossref
Crossref
Mahshid Mehdizadeh, Behrouz Farhadihosseinabadi, Maryam Nikoonezhad, Ghazaleh Sankanian, Masoud Soleimani & Arezou Sayad. (2021) Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs. Journal of Oncology Pharmacy Practice 28:1, pages 149-158.
Crossref
Crossref
Simone Zocchi, Antoine David, Michele Goodhardt & David Garrick. 2022. Clinical Applications of Non-Coding RNAs in Cancer. Clinical Applications of Non-Coding RNAs in Cancer
97
140
.
Seiichi Okabe, Yuko Tanaka & Akihiko Gotoh. (2021) Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. Experimental Hematology & Oncology 10:1.
Crossref
Crossref
Federica Mannino, Giovanni Pallio, Roberta Corsaro, Letteria Minutoli, Domenica Altavilla, Giovanna Vermiglio, Alessandro Allegra, Ali Eid, Alessandra Bitto, Francesco Squadrito & Natasha Irrera. (2021) Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells. Cancers 13:22, pages 5741.
Crossref
Crossref
Ingrid Spaan, Laura M. Timmerman, Thomas Kimman, Anne Slomp, Marta Cuenca, Niels van Nieuwenhuijzen, Laura M. Moesbergen, Monique C. Minnema, Reinier A. Raymakers & Victor Peperzak. (2021) Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma. Blood Advances 5:12, pages 2593-2607.
Crossref
Crossref
Femke A. I. Ehlers, Niken M. Mahaweni, Timo I. Olieslagers, Gerard M. J. Bos & Lotte Wieten. (2021) Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients. Frontiers in Oncology 11.
Crossref
Crossref
Xiaojun Chen, Wei Chen, Zin Mar Aung, Wenqing Han, Yan Zhang & Gang Chai. (2021) LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway. Bone & Joint Research 10:4, pages 237-249.
Crossref
Crossref
Yi Zhou, Zhimin Liu, Ernest C. Lynch, Leya He, Henghui Cheng, Lin Liu, Zhen Li, Jiangyuan Li, Lauren Lawless, Ke K. Zhang & Linglin Xie. (2021) Osr1 regulates hepatic inflammation and cell survival in the progression of non-alcoholic fatty liver disease. Laboratory Investigation 101:4, pages 477-489.
Crossref
Crossref
Hamed Mirzaei, Hossein Bagheri, Faezeh Ghasemi, Jaber M. Khoi, Mohammad H. Pourhanifeh, Yvan V. Heyden, Erfan Mortezapour, Ali Nikdasti, Philippe Jeandet, Haroon Khan & Amirhossein Sahebkar. (2021) Anti-Cancer Activity of Curcumin on Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry 21:5, pages 575-586.
Crossref
Crossref
Taewoong Choi, In Young Choi, Kyungdo Han, Su-Min Jeong, Jung Eun Yoo, Sang Youl Rhee, Yong-Gyu Park & Dong Wook Shin. (2021) Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects. Cancers 13:3, pages 540.
Crossref
Crossref
Ademar Dantas da Cunha Júnior, Dalila Luciola Zanette, Fernando Vieira Pericole, Sara Teresinha Olalla Saad & José Barreto Campello Carvalheira. (2021) Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?. Advances in Hematology 2021, pages 1-7.
Crossref
Crossref
Radhika Bansal, Sagar Rakshit, Weiguo Han & Shaji Kumar. (2021) Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma. Oncology & Haematology 17:1, pages 48.
Crossref
Crossref
Niels W C J van de Donk, Charlotte Pawlyn & Kwee L Yong. (2021) Multiple myeloma. The Lancet 397:10272, pages 410-427.
Crossref
Crossref
Samrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, Michael Bauer, Yan Wang, Shayu Deshpande, Judith Den, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Frits van Rhee, Gareth J. Morgan & Brian A. Walker. (2020) The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Sabah Akhtar, Tayyiba A. Ali, Ammara Faiyaz, Omar S. Khan, Syed Shadab Raza, Michal Kulinski, Halima El Omri, Ajaz A. Bhat & Shahab Uddin. (2020) Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma. International Journal of Molecular Sciences 21:14, pages 5002.
Crossref
Crossref
Paul G. Richardson, Arnon Nagler, Dina Ben‐Yehuda, Ashraf Badros, Parameswaran N. Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard LeBlanc, Sung‐Soo Yoon, Kihyun Kim, Joaquin Martinez‐Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake, Teru Hideshima, Kathleen Colson, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen & Kenneth C. Anderson. (2020) Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. eJHaem 1:1, pages 94-102.
Crossref
Crossref
Ningni Jiang, Qijie Dai, Xiaorui Su, Jianjiang Fu, Xuancheng Feng & Juan Peng. (2020) Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Molecular Biology Reports 47:6, pages 4587-4629.
Crossref
Crossref
Shuyan Liu, Yun Zhang, Chang Huang & Shengyun Lin. (2019) miR‐215‐5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway. Journal of Cellular Biochemistry 121:2, pages 1475-1490.
Crossref
Crossref
Mohamed Rizk, Ola Rizq, Motohiko Oshima, Yaeko Nakajima‐Takagi, Shuhei Koide, Atsunori Saraya, Yusuke Isshiki, Tetsuhiro Chiba, Satoshi Yamazaki, Anqi Ma, Jian Jin, Atsushi Iwama & Naoya Mimura. (2019) Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma. Cancer Science 110:12, pages 3695-3707.
Crossref
Crossref
Marcel Seibold, Thorsten Stühmer, Nadine Kremer, Anja Mottok, Claus-Jürgen Scholz, Andreas Schlosser, Ellen Leich, Ulrike Holzgrabe, Daniela Brünnert, Santiago Barrio, K. Martin Kortüm, Antonio G. Solimando, Manik Chatterjee, Hermann Einsele, Andreas Rosenwald, Ralf C. Bargou & Torsten Steinbrunn. (2019) RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica 105:9, pages 2316-2326.
Crossref
Crossref
Zaiqing Zhang, Gongzeng Luo, Chuandong Yu, Guisheng Yu, Rui Jiang & Xuefeng Shi. (2019)
Retracted
: MicroRNA‐493‐5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel‐like factor 5
. Journal of Cellular Physiology 234:8, pages 13525-13533.
Crossref
Crossref
Yun Jung Choi, Dong Ha Kim, Dok Hyun Yoon, Cheolwon Suh, Chang-Min Choi, Jae Cheol Lee, Jung Yong Hong & Jin Kyung Rho. (2019) Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. Scientific Reports 9:1.
Crossref
Crossref